Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)

Trial Profile

Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2010

At a glance

  • Drugs Abciximab (Primary) ; Clopidogrel
  • Indications Cardiovascular disorders; Embolism and thrombosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms BRAVE-3
  • Most Recent Events

    • 14 Apr 2009 Results published in Circulation.
    • 31 Mar 2009 Results were presented at the 58th Annual Scientific Session of the American College of Cardiology (ACC-2009).
    • 31 Mar 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top